Ocular Therapeutix reports additional week 52 data from wet AMD trial

April 13, 2026 7:01 AM

Ocular Therapeutix Inc. (NASDAQ: OCUL) announced additional week 52 data from its SOL-1 Phase 3 trial of AXPAXLI for wet ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found